Martín-Saborido Carlos, López-Alcalde Jesús, Ciapponi Agustín, Sánchez Martín Carlos Enrique, Garcia Garcia Elena, Escobar Aguilar Gema, Palermo Maria Carolina, Baccaro Fernando G
San Juan De Dios Foundation, Health Sciences University Centre, Antonio de Nebrija University, Research on Evidence and Decision Making Group, Paseo de la Habana 70 bis, Madrid, Comunidad de Madrid, Spain, 28036.
Cochrane Associate Centre of Madrid, Ctra. Colmenar Km. 9,100, Madrid, Madrid, Spain, 28034.
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD011725. doi: 10.1002/14651858.CD011725.pub2.
Among people who have suffered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it is estimated that about 11 people per 100 with traumatic brain injury die. Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately, restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury.
To assess the effects of indomethacin for adults with severe traumatic brain injury.
We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We also screened reference lists and conference abstracts, and contacted experts in the field.
Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery.
Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods.
We identified no eligible studies for this review, either completed or ongoing.
AUTHORS' CONCLUSIONS: We found no studies, either completed or ongoing, that assessed the effects of indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the effects of indomethacin on intracranial pressure, mortality rates, quality of life, disability or adverse effects. This absence of evidence should not be interpreted as evidence of no effect for indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.
在遭受创伤性脑损伤的人群中，颅内压升高仍是早期死亡的主要原因；据估计，每100名创伤性脑损伤患者中约有11人死亡。吲哚美辛（也称为消炎痛）是一种强效脑血管收缩剂，可降低颅内压，并最终恢复脑灌注和氧合。因此，吲哚美辛可能改善创伤性脑损伤患者的恢复情况。
评估吲哚美辛对重度创伤性脑损伤成人患者的影响。
我们从数据库建库至2019年8月23日进行检索。我们检索了Cochrane图书馆中的Cochrane对照试验中心注册库（CENTRAL；2019年第8期）、Ovid MEDLINE、Ovid Embase、CINAHL Plus（EBSCO）、其他四个数据库以及临床试验注册库。我们还筛选了参考文献列表和会议摘要，并联系了该领域的专家。
我们的检索标准包括随机对照试验（RCT），这些试验比较了吲哚美辛与任何对照措施，针对患有与颅内压升高相关的重度创伤性脑损伤且此前未进行减压手术的成人患者。
两位综述作者独立决定纳入的研究。我们遵循Cochrane的标准方法。
我们未找到该综述的合格研究，无论是已完成的还是正在进行的。
我们未找到已完成或正在进行的评估吲哚美辛对重度创伤性脑损伤继发颅内高压控制效果的研究。因此，我们无法就吲哚美辛对颅内压、死亡率、生活质量、残疾或不良反应的影响得出任何结论。缺乏证据不应被解释为吲哚美辛对控制重度创伤性脑损伤继发颅内高压无效的证据。这意味着我们尚未找到该综述的合格研究。
